Navigation Links
Nektar Therapeutics Reports First Quarter 2011 Financial Results
Date:4/27/2011

s; (ii) the timing of the commencement or end of clinical trials and the successful commercial launch of our drug candidates may be delayed or unsuccessful due to slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, regulatory delay, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iii) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of Nektar's technology platform to potential new drug candidates is therefore highly uncertain and unpredictable and one or more research and development programs could fail; (iv) Nektar's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required in the future; (v) the outcome of any future intellectual property or other litigation related to Nektar's proprietary product candidates or complex commercial agreements; and (vi) certain other important risks and uncertainties set forth in Nektar's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2011.  Actual results could differ materially from the forward-looking statements contained in this press release.  Nektar undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise.Nektar Investor Inquiries:Jennifer Ruddock/Nektar Therapeutics

(650) 631-4954Susan Noonan/SA Noonan Communications, LLC

(212) 966-3650Nektar Media Inquiries:Karen Bergman/BCC Partners

(650) 575-1509 Michelle Corral/BCC Partners

(415) 794-8662NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)(Unaudited)ASSETSMarch 31, 2011December 31, 201
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Dennis Winger Joins Nektar Therapeutics Board of Directors
2. Nektar Therapeutics Reports Third Quarter 2009 Financial Results
3. Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets
4. Nektar Therapeutics to Host Conference Call to Discuss Todays Announcement of a New Partnership for NKTR-118 and NKTR-119
5. AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation
6. Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
7. Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets
8. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
9. Nektar Therapeutics Reports First Quarter 2009 Financial Results
10. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
11. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... 31, 2014 2014 Market ... a professional and in-depth research report on ... Polyacrylamide information, including Polyacrylamide definition, classification, application, ... industry overview. This research covers the international ... as global industry analysis covering macroeconomic environment ...
(Date:8/30/2014)... The Global and China Electrical ... study on the current state of the Electrical ... The report provides a basic overview of the ... Global market analysis and Chinese domestic market analysis ... trends and competitive landscape of the market. A ...
(Date:8/29/2014)... based on electrons, but one of the most promising ... circuits based on light (photons) instead of electrons. First, ... stream of single photons and control their direction. Researchers ... to achieve this control, but now scientists at the ... stream of photons emitted one at a time and ...
(Date:8/29/2014)... According to a new market report published by Transparency ... valued at USD 3,754.6 million in 2012 and is estimated ... CAGR of 5.9% from 2013 to 2019. , Nearly half ... by bone and joint disorders, and this number is expected ... will continue to increase the demand for orthobiologics. Other factors ...
Breaking Biology Technology:International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3Breakthrough in light sources for new quantum technology 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
... of Multi-Use Clearance for Axxent(R), System ... Radiation Therapy, SUNNYVALE, Calif., May 21 ... from the U.S. Food & Drug Administration,(FDA) for ... System for the treatment of endometrial cancer. Previously,cleared ...
... Co., Ltd. announced today,that it has entered into an ... a German biotechnology company focusing on research into,antibodies for ... 100 percent of the stock and make a,one-time payment ... Closure of the transaction is subject to clearance under ...
... world converge on Regenesis, SCOTTSDALE, Ariz., May ... that markets the Provant(R) Wound Therapy,System, announced today ... purpose is to guide advanced scientific investigations into ... and further,application of Regenesis, platform technology to clinical ...
Cached Biology Technology:FDA Clears New Applicators for Endometrial Cancer Treatment With Xoft's Axxent(R) Electronic Brachytherapy System 2FDA Clears New Applicators for Endometrial Cancer Treatment With Xoft's Axxent(R) Electronic Brachytherapy System 3FDA Clears New Applicators for Endometrial Cancer Treatment With Xoft's Axxent(R) Electronic Brachytherapy System 4Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG 2Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG 3Regenesis Biomedical Appoints Scientific Advisory Board Composed of Life Science and Electronics Experts 2Regenesis Biomedical Appoints Scientific Advisory Board Composed of Life Science and Electronics Experts 3
(Date:9/2/2014)... in Taiyuan, China, have substantially improved the health of ... reduction in costs associated with loss of life and ... the Columbia Center for Children,s Environmental Health (CCCEH) at ... University, the Center of Diseases Control and Prevention of ... Health. , The study is the first to document ...
(Date:9/2/2014)... of lithographic limestone is well known as a ... that area (for example, Archaeopteryx). Now, for the ... the French equivalent of these outcrops - discoveries ... known water treader. , Despite the abundance of ... have been obtained from the Late Kimmeridgian equivalents ...
(Date:9/2/2014)... done in by it. New research at Rockefeller University ... gap in mice with very similar genetic backgrounds ... the development of psychiatric disorders such as anxiety and ... as it goes through its life. And we suspect ... genes, and as a result, affect an animal,s susceptibility ...
Breaking Biology News(10 mins):Clean air halves health costs in Chinese city 2Exceptionally well preserved insect fossils from the Rhône Valley 2Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3
... Cheryl Hayashi, a biologist at UC Riverside and a national ... a $500,000 MacArthur Fellowship, one of the most prestigious awards ... MacArthur Fellows for 2007 named by the John D. and ... award, the MacArthur Fellowship is a no strings attached grant ...
... help policy makers to estimate the consequences of various ... much toll must be charged for the desired policy ... all travellers or maximising the toll incomes (revenues). Based ... the impacts on road congestion and the total toll ...
... antimicrobials bind and thereby get inactivated in the mucus ... may have found a way to help cystic fibrosis ... this work has potential as a therapeutic strategy against ... professor of materials science and engineering, of physics, and ...
Cached Biology News:UC Riverside biologist receives prestigious MacArthur Fellowship 2UC Riverside biologist receives prestigious MacArthur Fellowship 3Cystic fibrosis patients may breathe easier, thanks to bioengineered antimicrobials 2
...
... Ferrofluid products perform optimally when ... Systems MagCellect Magnet. To accommodate ... iron boron permanent magnet holds ... mm test tubes or two ...
S. O'Hare & C.K. Atterwill • In vitro toxicity techniques for regular lab use. Ex vivo techniques are also covered with the aim of reducing and refining the use of animals in the future....
Agarase cleaves agarose to neoagaro-oligosaccharides, and is used for,quantitative, gentle recovery of DNA from low melting point agarose....
Biology Products: